WVE PE Ratio & Valuation,Is WVE Overvalued

WVE Relative Valuation

WVE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WVE is overvalued; if below, it's undervalued.

Historical Valuation

WAVE Life Sciences Ltd (WVE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 63.89 is considered Overvalued compared with the five-year average of -5.07. The fair price of WAVE Life Sciences Ltd (WVE) is between 2.14 to 6.14 according to relative valuation methord. Compared to the current price of 16.56 USD , WAVE Life Sciences Ltd is Overvalued By 169.8%.

Relative Value

Fair Zone

2.14-6.14

Current Price：16.56

169.8%

Overvalued

-13.57

-12.75

EV/EBITDA

WAVE Life Sciences Ltd. (WVE) has a current EV/EBITDA of -12.75. The 5-year average EV/EBITDA is -2.43. The thresholds are as follows: Strongly Undervalued below -9.07, Undervalued between -9.07 and -5.75, Fairly Valued between 0.89 and -5.75, Overvalued between 0.89 and 4.21, and Strongly Overvalued above 4.21. The current Forward EV/EBITDA of -12.75 falls within the Strongly Undervalued range.

-11.53

EV/EBIT

WAVE Life Sciences Ltd. (WVE) has a current EV/EBIT of -11.53. The 5-year average EV/EBIT is -3.53. The thresholds are as follows: Strongly Undervalued below -9.71, Undervalued between -9.71 and -6.62, Fairly Valued between -0.44 and -6.62, Overvalued between -0.44 and 2.66, and Strongly Overvalued above 2.66. The current Forward EV/EBIT of -11.53 falls within the Strongly Undervalued range.

63.89

WAVE Life Sciences Ltd. (WVE) has a current PS of 63.89. The 5-year average PS is 14.05. The thresholds are as follows: Strongly Undervalued below -5.24, Undervalued between -5.24 and 4.41, Fairly Valued between 23.69 and 4.41, Overvalued between 23.69 and 33.33, and Strongly Overvalued above 33.33. The current Forward PS of 63.89 falls within the Strongly Overvalued range.

-14.71

P/OCF

WAVE Life Sciences Ltd. (WVE) has a current P/OCF of -14.71. The 5-year average P/OCF is -6.20. The thresholds are as follows: Strongly Undervalued below -17.61, Undervalued between -17.61 and -11.91, Fairly Valued between -0.49 and -11.91, Overvalued between -0.49 and 5.22, and Strongly Overvalued above 5.22. The current Forward P/OCF of -14.71 falls within the Undervalued range.

-15.81

P/FCF

WAVE Life Sciences Ltd. (WVE) has a current P/FCF of -15.81. The 5-year average P/FCF is -5.48. The thresholds are as follows: Strongly Undervalued below -14.51, Undervalued between -14.51 and -9.99, Fairly Valued between -0.96 and -9.99, Overvalued between -0.96 and 3.56, and Strongly Overvalued above 3.56. The current Forward P/FCF of -15.81 falls within the Strongly Undervalued range.

WAVE Life Sciences Ltd (WVE) has a current Price-to-Book (P/B) ratio of 21.38. Compared to its 3-year average P/B ratio of -29.27 , the current P/B ratio is approximately -173.04% higher. Relative to its 5-year average P/B ratio of -126.81, the current P/B ratio is about -116.86% higher. WAVE Life Sciences Ltd (WVE) has a Forward Free Cash Flow (FCF) yield of approximately -7.16%. Compared to its 3-year average FCF yield of -11.95%, the current FCF yield is approximately -40.12% lower. Relative to its 5-year average FCF yield of -25.01% , the current FCF yield is about -71.37% lower.

21.38

P/B

Median3y

-29.27

Median5y

-126.81

-7.16

FCF Yield

Median3y

-11.95

Median5y

-25.01

Competitors Valuation Multiple

The average P/S ratio for WVE's competitors is 55.70, providing a benchmark for relative valuation. WAVE Life Sciences Ltd Corp (WVE) exhibits a P/S ratio of 63.89, which is 14.72% above the industry average. Given its robust revenue growth of -199.11%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of WVE increased by 33.87% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -7.56 to -22.34.

The secondary factor is the Margin Expansion, contributed 37.65%to the performance.

Overall, the performance of WVE in the past 1 year is driven by P/E Change. Which is more unsustainable.

-199.11%

-7.68M → 7.61M

Revenue Growth

37.65%

-514.22 → -707.83

Margin Expansion

195.33%

-7.56 → -22.34

P/E Change

33.87%

12.37 → 16.56

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is WAVE Life Sciences Ltd (WVE) currently overvalued or undervalued?

What is WAVE Life Sciences Ltd (WVE) fair value?

WVE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of WAVE Life Sciences Ltd (WVE) is between 2.14 to 6.14 according to relative valuation methord.

How does WVE's valuation metrics compare to the industry average?

What is the current P/B ratio for WAVE Life Sciences Ltd (WVE) as of Dec 15 2025?

As of Dec 15 2025, WAVE Life Sciences Ltd (WVE) has a P/B ratio of 21.38. This indicates that the market values WVE at 21.38 times its book value.

What is the current FCF Yield for WAVE Life Sciences Ltd (WVE) as of Dec 15 2025?

As of Dec 15 2025, WAVE Life Sciences Ltd (WVE) has a FCF Yield of -7.16%. This means that for every dollar of WAVE Life Sciences Ltd’s market capitalization, the company generates -7.16 cents in free cash flow.

What is the current Forward P/E ratio for WAVE Life Sciences Ltd (WVE) as of Dec 15 2025?

As of Dec 15 2025, WAVE Life Sciences Ltd (WVE) has a Forward P/E ratio of -13.57. This means the market is willing to pay $-13.57 for every dollar of WAVE Life Sciences Ltd’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for WAVE Life Sciences Ltd (WVE) as of Dec 15 2025?

As of Dec 15 2025, WAVE Life Sciences Ltd (WVE) has a Forward P/S ratio of 63.89. This means the market is valuing WVE at $63.89 for every dollar of expected revenue over the next 12 months.

WVE Valuation